Galapagos, Amsterdam Molecular Therapeutics, Netherlands Institute for Brain Research and Vrije Universiteit Amsterdam cooperate
Galapagos, Amsterdam Molecular Therapeutics B.V. (AMT), the Netherlands Institute for Brain Research (NIBR), and the Vrije Universiteit Amsterdam (VUA) announce their collaboration to develop innovative treatments for acute spinal cord and peripheral nerve damage (neurotrauma). The research collaboration will combine the cutting-edge expertise of four Dutch organizations and will be funded in part by a 2 million Euro grant from the Dutch governmental organization Senter.
The project will focus on developing innovative therapeutics to promote nerve regeneration and to diminish the effect of neural scarring, one of the main causes for the failure of the traumatically injured spinal cord and peripheral nerve to regenerate. According to the terms of the collaboration, Galadeno, Galapagos' partnering division, will provide access to its functional genomics platform on a fee-for-service basis. Access to this technology will enable the partners to discover protein targets involved in regeneration of injured nerve tissue.
Once these targets have been identified, AMT will further develop novel technologies based on their gene therapy platform. NIBR will use its expertise in neuroregeneration as well as micro-array technology and the VUA will contribute its state-of-the-art capabilities for analyzing nerve cell growth to further develop the therapeutics.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
